- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00869323
Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders
Phase II Trial of Bortezomib and Rituximab for Patients With Post Transplant Lymphoproliferative Disorders (PTLD)
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with rituximab may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving bortezomib together with rituximab works in treating patients with post-transplant lymphoproliferative disorders.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- To estimate the overall (complete and partial) response rates in patients with CD20+ post-transplant lymphoproliferative disorders treated with bortezomib and rituximab.
Secondary
- To evaluate the duration of remission, time to treatment failure, relapse-free survival, and overall survival of these patients.
- To characterize the quantitative and qualitative toxicities of this regimen.
OUTLINE:
- Induction therapy: Patients receive bortezomib intravenously (IV) and rituximab IV on days 1, 8, 15, and 22.
Patients achieving complete remission (CR) after completion of induction therapy proceed to maintenance therapy after 6 months of rest. Patients achieving partial remission (PR) or stable disease after completion of induction therapy receive additional bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR/PR after completion of bortezomib therapy proceed to maintenance therapy after 3 months of rest.
- Maintenance therapy: Patients receive bortezomib IV and rituximab IV on days 1, 8, 15, and 22. Treatment repeats every 6 months for 4 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Medical Center - Fairview
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine - Oncology Division
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed CD20+ B-cell post-transplant lymphoproliferative disorder
- Has undergone prior solid organ transplant
- Measurable disease as defined by Non-Hodgkin Lymphoma Response Criteria
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Absolute neutrophil count (ANC) ≥ 1,000/mm³
- Platelet count ≥ 75,000/mm³
- Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 40 mL/min
- Alanine transaminase (ALT) and Aspartate aminotransferase (AST) ≤ 3 times upper limit of normal
- Total bilirubin ≤ 2.0 mg/dL
Exclusion Criteria:
- Pregnant or nursing
- Fertile patients must use effective contraception during and for 3 months after completion of study treatment
- Peripheral neuropathy ≥ grade 2
- Known lymphomatous meningitis or central nervous system (CNS) involvement
- HIV infection
- Uncontrolled infection
- Myocardial infarction within the past 6 months or uncontrolled angina
- New York Heart Association class III-IV heart failure
- Severe uncontrolled ventricular arrhythmias
- Evidence of acute ischemia or active conduction system abnormalities by electrocardiogram (EKG)
- Concurrent serious medical or psychiatric disorder (e.g., active infection or uncontrolled diabetes) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study
- Diagnosis or treatment for another malignancy within the past 3 years, except completely resected basal cell carcinoma or squamous cell carcinoma of the skin, in situ malignancy, or curatively treated low-risk prostate cancer
- Known hypersensitivity to rituximab, bortezomib, boron, or any of the other agents used in this study
- Less than 14 days since prior investigational drugs
- Less than 4 weeks since prior bortezomib therapy (12 weeks for rituximab) and recovered from toxic effects prior to enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treated Patients
This group includes patients receiving Bortezomib and Rituximab for post-transplant lymphoproliferative disorders (PTLD).
|
375 mg/m^2 intravenously on Days 1,8, 15 and 22
Other Names:
1.3 mg/m^2 intravenous bolus days 1, 8, 15 and 22
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Patients With Overall (Complete and Partial) Response Rates
Time Frame: Day 1 to 2 Years Post Treatment
|
Day 1 to 2 Years Post Treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Relapse-free Survival
Time Frame: at 2 years
|
at 2 years
|
Remission Duration Among Patients Who Respond to Treatment
Time Frame: Day 1 to 8 Months Post Treatment
|
Day 1 to 8 Months Post Treatment
|
Time to Treatment Failure
Time Frame: Day 1 to Time of Disease Progression
|
Day 1 to Time of Disease Progression
|
Overall Survival
Time Frame: at 2 years
|
at 2 years
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2008LS043
- MT2008-05R (Other Identifier: Blood and Marrow Transplantation Program)
- 0806M37121 (Other Identifier: IRB, University of Minnesota)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoproliferative Disorder
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
Timothy VoorheesRecruitingPolymorphic Post-Transplant Lymphoproliferative Disorder | Monomorphic B-Cell Post-Transplant Lymphoproliferative DisorderUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedLymphoproliferative DisorderUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Lymphoproliferative Disorder | Refractory Lymphoproliferative DisorderUnited States
-
Charite University, Berlin, GermanyTerminatedPost-transplantation Lymphoproliferative DisorderAustralia, France, Germany, Sweden
-
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbHCompletedPosttransplant Lymphoproliferative DisorderGermany
-
Invivoscribe, Inc.RecruitingB-Cell Lymphoproliferative DisorderUnited States, Germany, Japan
-
University of EdinburghUnknownLymphoproliferative DisorderUnited Kingdom
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedLymphoproliferative DisorderCanada, United States, Australia, New Zealand
-
Deepa JagadeeshTerminatedPost-transplant Lymphoproliferative DisorderUnited States
Clinical Trials on rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
PfizerCompletedRheumatoid ArthritisUnited States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
-
Mabion SAParexelWithdrawn
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States